ReviewCurrent opinion in infectious diseases2025
Dengue encephalitis: what's new?
Review in Current opinion in infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- NS2A V89F mutation in a DENV1 clinical isolate enhances neurotropism and neuroinvasion.Frontiers in cellular and infection microbiology · 2026Article
- Fulminant cerebral edema in the setting of acute dengue fever after mechanical thrombectomy in a patient with massive stroke and severe hypoalbuminemia: a case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewNeurological manifestations of dengue (NeuroDengue) are uncommon but can often mimic those of other tropical infections. This review aims to present new insights on dengue encephalitis, emphasizing pathogenesis, clinical features, and diagnostic challenges. We highlight unique neuroimaging patterns, observed through MRI, which may aid in diagnosing NeuroDengue. The aim is to significantly enhance early recognition and management of this underreported but severe complication of dengue, providing valuable insights for healthcare professionals. RECENT
findingsRecent research has improved our understanding of dengue encephalitis and the neurotropism of the dengue virus in regions such as the thalamus, basal ganglia, and cortex. Notable MRI findings include the 'double doughnut' sign and microhaemorrhages, although these findings are nonspecific and may also appear in other flavivirus encephalitides. A definitive diagnosis requires a positive cerebrospinal fluid (CSF) PCR for the dengue virus, often combined with antibody testing in both CSF and serum. Additionally, elevated levels of IL-6 and TNF-α in CSF indicate enhanced inflammatory responses, which strengthens the early identification of dengue encephalitis and informs potential management strategies. SUMMARY: Evidence affirms the neurotropic nature of dengue, confirmed by positive CSF PCR results. MRI typically reveals T2 hyperintensities in specific brain areas, along with the presence of micro-haemorrhages, and the 'double doughnut' sign. Recent advancements in diagnostics include analysing CSF dengue antibody indices and neuroinflammatory markers. Dengue serotypes 2 and 3 exhibit heightened neurovirulence, with seizures occurring in 30-40% of cases. While supportive management with fluids is crucial, a subset of patients may benefit from intravenous, immunoglobulin (IVIG) and steroids. Early identification of dengue encephalitis could significantly improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.